To test the utility of CTLA4 methylation as a predictive biomarker for response to anti-CTLA-4 immune checkpoint blockade in stage IV melanoma patients, we identified retrospectively 30 patients diagnosed with advanced melanoma and treated with anti-CTLA-4 antibody ipilimumab monotherapy. Here, CTLA4 is linked to melanoma.